NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
Clinical Trials
4 trialsNCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT05840510 2025-04-25
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT05263986 2023-02-27
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1 Unknown